Abstract:Non-small-cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers worldwide with limited effective therapies. Cisplatin (DDP), as the first-line treatment, is always served as a mainstay of chemotherapeutic agents in combination with other drugs for NSCLC treatment. Nevertheless, DDP-based therapy is limited due to the frequent development of chemoresistance and adverse effects. Herein, it is necessary to find a more effective therapeutic approach with less toxicity. Falnidamol (FLD) is a pyrimido-pyrimidine compound and exerts anti-cancer activity. In the present study, we found that FLD could strongly promote the cytotoxicity of DDP and markedly reduce the IC50 values to restrain the proliferation of NSCLC cells. Furthermore, combination of FLD and DDP remarkably induced G2/M cell cycle arrest, DNA damage and mitochondrial apoptosis, which was largely through the induction of reactive oxygen species (ROS). Additionally, FLD/DDP in combination greatly triggered ferroptosis, along with free iron accumulation and enhanced lipid peroxidation. Epithelial to mesenchymal transition (EMT) and epidermal growth factor receptor (EGFR) phosphorylation were also considerably restrained in NSCLC cells co-treated with FLD/DDP. Mechanistically, the combinative treatment significantly reduced DUSP26 expression in NSCLC cells. More studies showed that DUSP26 was strongly up-regulated in human NSCLC samples compared with the paired normal tissues, and high DUSP26 predicted poor overall survival rate among patients. Importantly, we found that DUSP26 suppression intensively reduced the proliferation, EMT process and pEGFR expression in NSCLC cells, whereas facilitated ROS production, DNA damage and cell death; however, opposite phenotype was observed in NSCLC cells over-expressing DUSP26. More importantly, DUSP26 over-expression completely abolished the anti-cancer function of FLD/DDP in NSCLC cells. Animal studies finally confirmed that FLD/DDP in combination efficiently reduced tumor growth and lung metastasis in mice with ameliorated side effects. In conclusion, all these data illustrated that FLD and DDP combinational treatment effectively restrained NSCLC progression, and thus can be served as a promising therapeutic strategy.

Synergistic Effect of Endostatin and Cisplatin on Calu-6 Lung Cancer Cells

Effect of Alarelin Combined with Cisplatin on Subcutaneous Xenograft of Human Endometrial Carcinoma in Nude Mice

Efficient Killing Effect of Osteosarcoma Cells by Cinobufacini and Cisplatin in Combination.

Synergistic Apoptotic Effect of Crocin and Cisplatin on Osteosarcoma Cells Via Caspase Induced Apoptosis.

[Biological Effect of Endostatin on Transplanted Human Lung Adenocarcinoma Calu-6 Tumor in Nude Mice].

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model

Synergistic effect of ethaselen and cisplatin treatment against tumor cell lines

Radiosensitization of Recombinant Human Endostatin in Human Lung Squamous Cancer Cells in Vitro

Rh-endostatin (YH-16) in Combination with Chemotherapy for Advanced Non-Small Cell Lung Cancer: A Clinical Observation

Antineoplastic effects of Endostar combined with combretastatin A4 phosphate in vitro

The effect of calycosin-7-O-β-D-glucoside and its synergistic augmentation of cisplatin-induced apoptosis in SK-OV-3 cells.

Endostatin Sensitizes p53-Deficient Non-Small Cell Lung Cancer to Genotoxic Chemotherapy by Targeting DNA-PKcs.

Experimental Study on the Synergistic Anti- Cervical Cancer Effect of Disulfiram and Cisplatin Via Endoplasmic Reticulum Stress

Synergistic Inhibitory Effects of Endostatin and Radiation Therapy on Angiogenesis of Lewis Lung Cancer in Nude Mice

Clinical Efficiency of Rh-Endostatin Combined with Vincristine and Cisplatin in the Treatment of Non-Small Cell Lung Cancer

Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways

Arsenic Trioxide Exerts Synergistic Effects with Cisplatin on Non-Small Cell Lung Cancer Cells Via Apoptosis Induction

Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway

Mechanism of Radiosensitizing Effects of Endostatin on H-520 Human Lung Squamous Cancer Cells

Synergistic induction of apoptosis by combination treatment of sinomenine with cisplatin in human fibrosarcoma HT-1080 cells